Tibbiyah Reports SAR 18.83M Net Loss in the Six Months 2026
TIBBIYAH 9530.SA | 0.00 |
On 2026-08-23 08:09:33 (Saudi Time), Arabian International Healthcare Holding Co. announced its Interim financial results for the six months ended on June 30, 2026.
| Element List | Current Period | Similar period for previous year | %Change | ||
|---|---|---|---|---|---|
| Sales/Revenue | 312,708 | 314,195 | -0.473 | ||
| Net Profit (Loss) Attributable to Shareholders of the Issuer | -18,828 | -24,290 | -22.486 | ||
| Total Shareholders Equity (after Deducting Minority Equity) | 346,334 | 320,128 | 8.186 | ||
| Profit (Loss) per Share | -0.95 | -1.23 | |||
| All figures are in (Thousands) Saudi Arabia, Riyals | |||||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Thousands) Saudi Arabia, Riyals | |||
| Element List | Explanation |
|---|---|
| The reason of the increase (decrease) in the sales/ revenues during the current period compared to the same period of the last year is | Arabian International Healthcare Holding Co. (“The Company” or “Tibbiyah”) reported revenue of SAR 312.7 million for H1-FY26, largely in line with SAR 314.2 million in H1-FY25, reflecting a slight decline of 0.5%. Medical supplies revenue grew 7.6% year-on-year (YoY) to SAR 176.4 million, due to strong overall performance across the segment, offsetting a decline in Medical Equipment revenue, highlighting the strength of the Company’s diversified portfolio. |
| The reason of the increase (decrease) in the net profit during the current period compared to the same period of the last year is |
The company registered a net loss attributable to shareholders of SAR 18.8 million in H1-FY26 an improvement from a net loss of SAR 24.3 million in H1-FY25.
Revenues: Tibbiyah reported revenues of SAR 312.7 million in H1 2026 compared to SAR 314.2 million in H1 2025, largely in line compared to last year same period (-0.5%) YoY. Growth in Medical Supplies of +7.6% YoY broadly offset the decline in Medical Equipment of -9.3% YoY, reflecting the Company’s ability to diversify its revenue base across Medical Equipment and Medical Supplies.
Gross Profit: Gross profit of SAR 71.6 million in H1 2026 compared to SAR 69.5 million in H1 2025, reflecting a 3.1% increase YoY, with margin expanding 80bps to 22.9% from 22.1%. This improvement reflects margin gains across both Medical Equipment and Medical Supplies, supported by better cost management and product mix during the period.
Net Loss: Net loss attributable to shareholders narrowed to SAR 18.8 million in H1 2026, compared to a net loss of SAR 24.3 million in H1 2025, primarily due to higher operating profit and a net reversal of expected credit losses on trade receivables, partially offset by higher finance costs and general and administrative expenses. |
| Statement of the type of external auditor's report | Unmodified conclusion |
| Reclassification of Comparison Items |
During the period, the Group has reclassified certain comparative amounts have been reclassified to conform to the current-year presentation. The net result of activities that do not form part of the Group’s ordinary operations, previously presented on a gross basis within revenue and cost of revenue, amounting to 1.3 million and 1.2 million respectively, has been reclassified to other income on a net basis, amounting to 0.1 million, to better reflect the nature of the underlying transactions. This reclassification represents a change in presentation only and had no impact on profit for the year, total equity or cash flows.
In December 2025, the Group sold its controlling share in Innovative Healthcare Holding Ltd, refer note 9. Comparative information for prior periods has been re-presented to show the results of the discontinued segment separately, in accordance with IFRS 5. |
| Additional Information |
Basic and diluted losses per share are calculated by dividing the losses for the period by the weighted average number of outstanding shares during the period. There were no potentially dilutive shares or options in the period, therefore no difference between the basic and the diluted losses per share.
please refer to the attached File for H1 2026 Earning Release |
Year-on-Year Performance Drivers
Sales/Revenue declined marginally by 0.473% YoY from SAR 312.71 million to SAR 312.71 million (SAR 314.195 thousand converted: SAR 314.20 million vs SAR 312.71 million), as growth in Medical Supplies revenue of 7.6% YoY to SAR 176.4 million was largely offset by a 9.3% YoY decline in Medical Equipment revenue. The net loss attributable to shareholders narrowed by 22.486% YoY from SAR 24.29 million to SAR 18.83 million, primarily driven by higher operating profit, an improvement in gross profit margin (expanding 80bps to 22.9%), and a net reversal of expected credit losses on trade receivables, partially offset by higher finance costs and increased general and administrative expenses.
Other Items
Arabian International Healthcare Holding Co. reported an unmodified conclusion from its external auditor for the six-month period ending June 30, 2026. Gross profit reached SAR 71.6 million in H1 2026, up from SAR 69.5 million in H1 2025, reflecting a 3.1% increase YoY with gross margin expanding 80bps to 22.9% from 22.1%, supported by better cost management and product mix. Total shareholders' equity (after deducting minority equity) stood at 346,334(currency not specified in original) thousand, compared to 320,128(currency not specified in original) thousand in the same period of the prior year, an increase of 8.186%. Loss per share improved to -0.95 from -1.23 in the prior year period. During the period, the Group reclassified certain comparative amounts to conform to the current-year presentation, whereby net results of activities not forming part of ordinary operations, previously presented on a gross basis within revenue and cost of revenue amounting to 1.3(currency not specified in original) million and 1.2(currency not specified in original) million respectively, were reclassified to other income on a net basis amounting to 0.1(currency not specified in original) million; this reclassification had no impact on profit, total equity, or cash flows. Additionally, in December 2025, the Group sold its controlling share in Innovative Healthcare Holding Ltd, and comparative information for prior periods has been re-presented to show the results of the discontinued segment separately in accordance with IFRS 5.
Original announcement:
https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anId=97734&anCat=1&cs=9530&locale=arAttached PDF document link:
https://www.saudiexchange.sa/Resources/fsPdf/19992_2903_2026-08-22_18-30-18_en.pdfImportant Notice: The announcement information and market data in this report are sourced directly from the Saudi Exchange (Tadawul). This summary is generated by Sahm’s proprietary AI model for informational purposes only. While we strive for accuracy, it should not be construed as financial advice or an investment recommendation.